• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glucose monitor maker LifeScan is set to emerge from Ch. 11 bankruptcy

October 28, 2025 By Sean Whooley

LifeScan OneTouch appLifeScan announced that its Chapter 11 bankruptcy reorganization plan received U.S. Bankruptcy Court approval.

The U.S. Bankruptcy Court for the Southern District of Texas approved the company’s Chapter 11 plan. With the approval, LifeScan said it’s positioned to emerge from its financial restructuring process by the end of the year.

Malvern, Pennsylvania-based LifeScan said in July that it entered into a restructuring support agreement and, to implement it, filed for Chapter 11. At the time, it said it expected to emerge from the process under the majority ownership of a group of existing lenders. It plans for the restructuring to “transform its balance sheet” while positioning it for a stronger, more profitable future. The company expects to reduce more than 75% of its debt to accelerate strategic investments that support its future.

LifeScan said that, upon emergence, its existing lenders, including Canyon Partners and Brigade Capital Management, will hold majority ownership. It said those parties strongly believe in its growth prospects within the glucose management industry.

The company develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app. It aims to provide simplicity, accuracy and trust in diabetes management.

“Today’s approval marks a significant milestone in our financial restructuring process,” said Valerie Asbury, CEO of LifeScan. “I am deeply grateful for the support of our financial partners and the unwavering commitment of our employees, which have enabled us to stay focused on delivering on our mission for more than 20 million people in over 50 countries. This balance sheet restructuring provides a stronger foundation for LifeScan to support our base business, advance new growth strategies, and commence our journey to become one of the most comprehensive players in the glucose management space.”

Filed Under: Business/Financial News, Diabetes, Featured, Legal News, Patient Monitoring, Technology, Wall Street Beat Tagged With: lifescan

IN CASE YOU MISSED IT

  • Billie Jean King supports Medtronic Diabetes awareness initiative
  • Tandem stock rises after hours on Q3 beats, record sales
  • Insulet leadership talks patch pump competition, expanding type 2 diabetes market
  • Insulet increases guidance again on Q3 beats, 30% sales uptick
  • Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS